Topic: chief medical officer
Sensei Biotherapeutics named Ildiko Csiki as CMO. Csiki was previously VP of immuno-oncology clinical development at Inovio Pharmaceuticals.
Sanofi’s global head of diabetes late-stage development, Eckhard Leifke, will move to Omeros to be its CMO and VP of clinical development.
Beijing’s CANbridge Life Sciences, developing Western drug candidates in China and Asia, brought on Pfizer’s May Orfali to be chief medical officer.
Sublimity Therapeutics hired Jesse Hall as chief medical officer, as it looks to move its lead candidate into a phase 2b ulcerative colitis study.
T-cell developer Tmunity named Immunocore’s Christina Coughlin as CMO as it preps for early cancer studies after raising $135 million in VC funding.
Syntimmune has named Vertex’s Mario Saltarelli as chief medical officer, following several leadership changes at the company over the past 18 months.
Ablynx CMO Robert Zeldin is moving to Acceleron, to take over for longtime CMO Matthew Sherman, as it begins to get phase 3 data on luspatercept.
Sarepta brought on Biogen’s VP of late-stage programs, Gilmore O’Neill, as chief medical officer, after their previous hire left after 8 months.
James Pennington joined AzurRx BioPharma as CMO as the company aims to launch a phase 2 trial of its lead candidate in cystic fibrosis this year.
Galecto Biotech hired Richard Marshall, head of fibrosis discovery at GlaxoSmithKline, to be CMO as it moves into late-phase trials of its IPF drug.